ArticleAnnals of medicine2025
Real-world outcomes of early and deferred anti-VEGF treatment in diabetic macular oedema in patients with type 1 diabetes.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study.Scientific reports · 2026Article
- Therapeutic Outcomes of Anti-VEGF Agents Versus Corticosteroids in Diabetic Macular Edema: A Comparative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravitreal anti-vascular-endothelial growth factor (anti-VEGF) injections have revolutionized the treatment of diabetic macular oedema (DME). The effect of early initiation of anti-VEGF treatment with good baseline visual acuity on treatment outcomes was compared with that of deferred treatment in patients with type 1 diabetes (T1D) and DME. PATIENTS AND
methodsThis was a population-based real-world retrospective cohort study of anti-VEGF-treated T1D patients with DME between 2010-2020. The data included age, sex, diagnosis of T1D and DME, severity of retinopathy, vision, duration of DME, and number of injections.
resultsIn total, 266 anti-VEGF-treated DME episodes were included. The average age at the time of T1D diagnosis was 2517years. At the onset of DME, the patients were 5015 years old, the duration of T1D was 2513 years, and 68% had non-proliferative and 32% had proliferative diabetic retinopathy. An average of 5.8 (SD 4.9) and 6.6 (SD 4.9) injections were required in the early treatment (baseline BCVA ≥75) and deferred treatment (<75 ETDRS letters) groups, respectively (
conclusionEarly treatment of DME with higher baseline BCVA may result in better visual outcomes in T1D patients, and delayed treatment may decrease the possibility of recovery of visual acuity. The duration of DME and number of injections were similar in the early and deferred treatment groups. Efforts to maintain proper visual function in T1D patients with DME are beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.